Sun F, Banwait MK, Singhal S, Herrmann A, et al. Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer. Lung Cancer 2025;208:108747.
PMID: 40957338